在第二阶段试验中,Helus Pharma 的 HLP004 显示出强烈的焦虑缓解,但其在 2026 年 3 月 5 日的股价下跌了 20.5%. Helus Pharma's HLP004 showed strong anxiety relief in a Phase 2 trial, but its stock dropped 20.5% on March 5, 2026.

Helus Pharma报告说,对HLP004的第二阶段研究取得了积极的上线结果,显示HAM-A级患者在20毫克剂量上的焦虑症状减少6周,达到10.4点,反应率为67%,恢复率39%,达到6个月。 Helus Pharma reported positive top-line results from a Phase 2 study of HLP004, showing a 10.4-point mean reduction in anxiety symptoms on the HAM-A scale at six weeks for patients on the 20 mg dose, with 67% response and 39% remission rates at six months. 该公司计划在2026年后期公布其相关化合物HLP003有关主要抑郁症的数据。 The company plans to publish data on its related compound HLP003 for major depressive disorder in late 2026. 尽管结果如此,公司股票在2026年3月5日的市场前交易中下跌20.52%至6.78美元。 Despite the results, the company's stock fell 20.52% to $6.78 in pre-market trading on March 5, 2026.